Medidata and Syapse tackling precision medicine challenges in new partnership

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Artem_Egorov)
(Image: Getty/Artem_Egorov)
Medidata and Syapse have teamed up to develop a new suite of solutions, which will aim address precision medicine challenges and accelerate clinical research in oncology for trial sponsors.

Formed in 2010, Syapse’s services enable healthcare providers to implement precision medicine through its software platform, data sharing network, and industry partnerships.

Medidata, which provides cloud-based technology and data analytics for clinical research, has partnered with the San Francisco, CA-based company to “transform oncology clinical trials for the age of precision medicin​e.”

Glen de Vries, Medidata president and co-founder, told us the “ultimate objective is to allow trial sponsors to accelerate the process of clinical research in oncology​.”

Medidata's solutions are used by 18 of the top 25 pharmaceutical companies, while Syapse’s solutions power precision medicine for nearly 300 hospitals across the US.

Through the partnership, the companies aim to scale a new product offering to pharmaceutical companies and health systems.

We will build a suite of solutions that will focus on optimizing trial eligibility criteria based on true patient availability, expanding access to innovative trials by bringing them to community sites, and making it easier for oncologists and their care teams identify and enroll patients​,” said de Vries.

While precision medicine is a promising area of research, there are challenges associated with focusing on even smaller segments of patients,” ​he added. “Our partnership with Syapse will help address these challenges​.” 

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers